Description

Indication & Scope

Linperlisib Tablets is an oral targeted anti-tumor agent indicated for adult patients with relapsed or refractory follicular lymphoma who have received at least two lines of prior systemic therapies, applied as long-term monotherapy until disease progression or intolerable toxicities occur.

Mechanism
As a highly selective small-molecule PI3Kδ inhibitor, it specifically blocks the BCR signaling pathway activated in malignant B lymphocytes, reduces AKT phosphorylation, suppresses proliferation of lymphoma cells and induces tumor cell apoptosis to control follicular lymphoma progression.
Drug class
Class 1 innovative oral chemical drug, domestic original selective PI3Kδ inhibitor, targeted therapeutic agent for B-cell hematological malignancies.
Clinical use
Phase II trials demonstrate robust efficacy and controllable safety. Oral once-daily 80mg; dose reduction to 60mg/40mg for toxicity. First domestic PI3Kδ inhibitor for relapsed/refractory follicular lymphoma.

Specification

Generic Name	Linperlisib Tablets
Brand Name	Yintarui®
Ingredient	Linperlisib
Dosage Form	Film-coated Tablets
Package	20mg* 120 tablets/bottle
Conditions Treated	Adult patients with relapsed or refractory follicular lymphoma after at least two systemic therapies
Taboos	patients with hypersensitivity to linperlisib or any excipients
Place of origin	Jiangsu, China
Priscription Type	Prescription drug (Rx)
Storage Conditions	Sealed, store below 30℃, avoid light
Manufacturer	Jiangsu Xuantai Pharmaceutical Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA)
Approval number	H20220034
Date of Revision	January 27, 2026
Shelf Life	24 months

How to use ?

Recommended Dose: 80 mg once daily (4 tablets of 20mg each), taken orally whole without crushing; adjust to 60mg or 40mg daily if adverse reactions occur.

Time: Take once daily at fixed time, before or after meals; continue administration until disease progression or unmanageable toxicity.

Interaction: Avoid combined use with strong CYP3A inhibitors/inducers without close monitoring; prevent Pneumocystis jirovecii pneumonia during treatment. Oral administration only, no injection use.

Side effects: Mostly mild to moderate; common adverse reactions encompass diarrhea, neutropenia, elevated liver enzymes, rash, fatigue; rare severe interstitial lung disease, severe infection; fatal adverse reactions are extremely uncommon.

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support